08.16.11
The Osteoarthritis Research Society International (OARSI) has accepted for presentation and poster publication a study comparing BCM-95 curcumin combined with BosPure boswellia (from EuroPharma, Green Bay, WI) and the prescription drug celecoxib, which is sold under the brand name Celebrex in the U.S. The study is scheduled for presentation at the OARSI meeting in September.
The study compared a 500 mg blend of BCM-95 curcumin and BosPure boswellia administered twice daily, compared to 100 mg of celecoxib twice daily. Thirty volunteers participated in the 12-week study. Not only were pain and stiffness assessed, but liver, kidney and blood tests were done at each visit to assess safety and tolerability.
The study compared a 500 mg blend of BCM-95 curcumin and BosPure boswellia administered twice daily, compared to 100 mg of celecoxib twice daily. Thirty volunteers participated in the 12-week study. Not only were pain and stiffness assessed, but liver, kidney and blood tests were done at each visit to assess safety and tolerability.